Analyst Price Targets — LEGN
This site can’t be displayed in an embedded view
Some publishers block loading inside other sites for security reasons. You can open the article in a new tab instead.
Latest News for LEGN

Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fifteen research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a

ArrowMark Colorado Holdings LLC lowered its holdings in Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN) by 4.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 938,678 shares of the company's stock after selling 44,832 shares during the quarter. ArrowMark Colorado Holdings LLC

Capital International Investors decreased its stake in shares of Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN) by 13.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 941,600 shares of the company's stock after selling 140,873 shares during the quarter. Capital

Legend Biotech Corporation (LEGN) Q4 2025 Earnings Call Transcript

SOMERSET, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported financial results for the fourth quarter and year ended December 31, 2025, and key corporate highlights.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LEGN.
U.S. House Trading
No House trades found for LEGN.
Options Chain Settings
Changes apply instantly as you toggle. Tap Done when finished.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.
